Tesamorelin 20mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) that prompts the pituitary to release growth hormone, raising IGF-1 and notably reducing visceral (deep abdominal) fat[1][3]. Unlike most peptides on this site, tesamorelin is FDA-approved (brand Egrifta / Egrifta SV) for one specific indication: reducing excess abdominal fat in HIV-associated lipodystrophy. Any other use is off-label or research only. This page outlines the once-daily subcutaneous approach and is presented for research and educational purposes.

Add 3.0 mL bacteriostatic water to one 20 mg vial → ~6.67 mg/mL (6,667 mcg/mL).
2 mg (2000 mcg) once daily subcutaneously — the FDA-approved regimen — after an optional 1 mg first-week titration.
At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg; 1 mg ≈ 15 units and 2 mg ≈ 30 units on a U-100 syringe.
Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) (Egrifta SV is room-temperature stable); once reconstituted, refrigerate at 2–8 °C and do not freeze.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard FDA-Approved Protocol (3 mL = ~6.67 mg/mL)

Phase / Week(s)	Dose & Frequency	Volume (U-100 units / mL)
Week 1 (optional titration)	1 mg / 1000 mcg (1× daily)	15 units (0.15 mL)
Weeks 2–12+	2 mg / 2000 mcg (1× daily)	30 units (0.30 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 20 mg vial → final concentration ~6.67 mg/mL (6,667 mcg/mL).
Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously — the FDA-approved regimen — with an optional 1 mg first week for tolerability.
Easy measuring: At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg on a U-100 syringe, so the 2 mg dose reads at a clear 30 units.
Storage: Refrigerate the lyophilized vial at 2–8 °C (35.6–46.4 °F) (Egrifta SV is stable at room temperature); after reconstitution, refrigerate at 2–8 °C and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day, preferably in the evening to align with the body’s natural nocturnal growth-hormone release[2]. The 2 mg daily dose is the standard FDA-approved regimen for HIV-associated lipodystrophy[3][4]; a one-week titration at 1 mg may improve early tolerability.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution keeps the standard 2 mg dose at 30 units, where U-100 syringe markings are easy to read. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. Tesamorelin is a prescription medication; any therapeutic use should be supervised by a qualified clinician.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections at the standard 2 mg dose (after the optional Week 1 titration).

At 2 mg/day, a 20 mg vial covers about ten days, so plan for roughly 0.7 vials per week.
8 weeks: ~6 vials
12 weeks: ~9 vials
16 weeks: ~11 vials
Per injection: 1 syringe
8 weeks (once daily): ~56 syringes
16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 20 mg vial for reconstitution.
8 weeks (6 vials): ~18 mL → 2 bottles
16 weeks (11 vials): ~33 mL → 7 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the FDA-approved once-daily regimen.

▪Goal: Reduce visceral (deep abdominal) adipose tissue and improve lipid profiles through sustained GH/IGF-1 elevation[3][4].
▪Schedule: Daily subcutaneous injections; clinical use typically runs 12–26 weeks and is supported up to 52 weeks under medical supervision[3].
▪Dose: 2 mg (2000 mcg) once daily after an optional Week 1 titration at 1 mg.
▪Reconstitution: 3.0 mL bacteriostatic water per 20 mg vial gives ~6.67 mg/mL for accurate unit measurements.
▪Storage: Refrigerate the dry vial at 2–8 °C (Egrifta SV is room-temperature stable); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

The FDA-approved daily dosing approach, with an optional tolerability titration.

▪Week 1 (optional): 1 mg (1000 mcg) once daily to assess tolerability.
▪Weeks 2+: 2 mg (2000 mcg) once daily — the standard FDA-approved dose[3][4].
▪Frequency: One subcutaneous injection per day, preferably in the evening.
▪Cycle Length: Typically 12–26 weeks; trials support up to 52 weeks with monitoring[3].
▪Timing: Evening administration is recommended; rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) are stable at 20–25 °C (68–77 °F) before reconstitution[5].
▪Reconstituted (bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F)[5].
▪Reconstituted (sterile water): Use immediately and discard any unused portion[5].
▪Freeze–thaw: Do not freeze the reconstituted solution, and avoid repeated freeze–thaw cycles.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen (at least 2 inches from the navel), thighs and upper arms to reduce local irritation and lipohypertrophy[6].
▪Metabolic monitoring: Because tesamorelin strongly stimulates GH, IGF-1 should be monitored periodically and blood glucose watched in patients with diabetes[6].
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: Tesamorelin is a prescription medication, FDA-approved (as Egrifta / Egrifta SV) only for HIV-associated lipodystrophy; any other use is off-label or research and should follow applicable law and medical supervision.

How This Works

Tesamorelin is a synthetic, stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) — a 44-amino-acid peptide carrying a chemical modification that resists rapid breakdown[1].

It binds GHRH receptors on the pituitary gland, prompting the gland’s own pulsatile release of growth hormone (GH), which in turn raises circulating IGF-1[2]. Because it works through the body’s natural feedback loop rather than supplying GH directly, the GH release stays closer to a physiological pattern.
The downstream GH/IGF-1 signalling promotes lipolysis (the breakdown of stored fat) and favorable metabolic shifts. Its best-documented effect is a meaningful reduction of visceral adipose tissue — the deep abdominal fat — in people with HIV-associated lipodystrophy, alongside improved lipid profiles, over roughly 6–12 months of daily use[3][4].
Approval status: Unlike most peptides on this site, tesamorelin is FDA-approved (brand Egrifta / Egrifta SV) — but only for one specific indication: reducing excess abdominal fat in HIV-associated lipodystrophy. Other uses, such as general body-composition or anti-aging goals, are off-label or research and are presented here for educational purposes only.
Researchers also study tesamorelin for related questions — for example, reducing liver fat in NAFLD and exploring effects on age-related GH/IGF-1 decline — but those applications remain investigational[4].

Lifestyle Factors

Complementary habits that may support the protocol’s metabolic goals.

▪Nutrition: Favor a balanced, protein-forward diet to support the anabolic side of GH/IGF-1 signalling.
▪Activity: Combine resistance training with aerobic exercise to maximize fat loss and metabolic benefit.
▪Sleep: Aim for 7–9 hours of quality sleep to support natural GH pulsatility.
▪Stress: Manage stress through mindfulness or relaxation practices to support adherence and recovery.

Potential Benefits & Side Effects

Observations from clinical trials and FDA-approved use; individual results vary.

▪Visceral fat reduction: Meaningful reduction in visceral adipose tissue, measurable after about 3–6 months in HIV-associated lipodystrophy[3].
▪Lipid & liver-fat signals: Improved lipid profiles, with research interest in reducing liver fat in NAFLD[4].
▪Sustained tolerability: Generally well tolerated, with maintained benefits during continuous use up to 52 weeks[3].
▪Note on scope: Approved benefits are established for HIV-associated lipodystrophy; other uses (anti-aging, cognition) remain investigational[4].
▪Injection-site reactions: Mild redness, itching, pain or bruising at the injection area[6].
▪Musculoskeletal: Joint pain (arthralgia), muscle aches and mild peripheral edema; occasional carpal-tunnel-type tingling that is dose-dependent and reversible[6].
▪Metabolic: IGF-1 elevation requires monitoring; small HbA1c increases have been observed in some patients[6].
▪Contraindications: Active malignancy (GH stimulation may accelerate latent tumors), pregnancy, and known hypersensitivity to tesamorelin or mannitol[6].

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[7][8].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen at least 2 inches from the navel, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[8].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[7].
▪Skip aspiration for subcutaneous shots — it isn't needed[7].
▪Press the plunger slowly and steadily until it's fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[6].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for Tesamorelin (20 mg).

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Tesamorelin 20mg.

Tesamorelin (20mg Vial) Dosage Protocol Open source
1 FDA Prescribing Information (Egrifta / Egrifta SV) Tesamorelin is a stabilized synthetic analog of GHRH (1-44); approved indication, dosing and storage. View Source ↗ Open source
2 Tesamorelin (Subcutaneous route) – Drug Information Mayo Clinic / IBM Merative: mechanism, GH/IGF-1 stimulation, administration and timing. View Source ↗ Open source
3 J. Clin. Endocrinol. Metab. (2010) Effects of tesamorelin (TH9507), a GH-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 trials. View Source ↗ Open source
4 Safety and metabolic effects of tesamorelin Longer-term safety and metabolic effects, including visceral fat and lipid outcomes; research interest in NAFLD and aging. View Source ↗ Open source
5 Tesamorelin – LiverTox (NIH/NIDDK, 2018) Clinical and research information, including formulation storage (Egrifta vs Egrifta SV) and reconstitution handling. View Source ↗ Open source
6 Egrifta Medication Guide / NCBI Bookshelf Common adverse effects, contraindications (active malignancy, pregnancy, mannitol hypersensitivity), IGF-1 monitoring and site rotation. View Source ↗ Open source
7 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
8 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source

Contents